The pivotal phase III trial by Hodi et al. (2010) demonstrated that ipilimumab, an anti-CTLA-4 monoclonal antibody, significantly improved overall survival in metastatic melanoma, marking a paradigm shift in cancer immunotherapy [42]. This evidence concerns the gene CTLA4 and cancer.